did the fda stop semaglutide 🚨 Moves to Shut Down Mass-Market Compounded GLP-1s FDA is taking action to restrict widely marketed, non–FDA-approved compounded GLP-1 products, citing concerns over safety, quality, and misleading claims. As demand FDA Warns on Certain Forms

This product is indicated to assist weight loss as part of a weight management programme

Method development, data acquisition/processing and report generation are performed using fully-licensed, comprehensive chromatography system software in order to comply with regulatory data integrity requirements

Always follow the angle specified in your device IFU or by your trial team

"A paucity of data, not robust scientific evidence: a response to Johnston and Foreyt." Trends in Endocrinology & Metabolism 25.1 (2014): 2-4

This information can support a more personalized conversation about whether GLP-1 agonist therapy, dual-receptor compounds, or alternative approaches align with your metabolic needs